HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call
TORONTO , Oct. 24, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7, 2024 . The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian , Chief Executive Officer, and Mr. John Hanna , Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast .
CONFERENCE ID: 84749
DATE: Thursday, November 7, 2024
TIME: 8:30 a.m. ET
WEBCAST LINK: https://app.webinar.net/pK7MRDbWv52
TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or 1-416-945-7677
RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/4eQL014
TAPED REPLAY: 1-888-660-6345 or 1-289-819-1450
REPLAY CODE: 84749#
The taped replay will be available for 14 days and the archived webcast will be available for 365 days.
A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com . Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
